This registration contains the study protocol for a systematic review and meta-analysis evaluating the risk of falls associated with novel androgen receptor pathway inhibitors (enzalutamide, apalutamide, and darolutamide) in patients with advanced prostate cancer. The primary objective is to provide a drug-specific safety evaluation and determine if the increased risk of falls constitutes a uniform class effect or a drug-specific phenomenon, utilizing a refined statistical framework with REML models and 97.5% confidence intervals.
Wei et al. (Thu,) studied this question.